Related Experiment Video
Updated: May 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Generic antiretroviral drugs in developing countries: friends or foes?
David Zucman1, Seydou Camara, Jérome Gravisse
1aHôpital FOCH, Suresnes, France bFrance Expertise Internationale, Paris, France cPharmaco-Toxicology Department, Hôpital Bichat, Paris, France.
Abstract:
Although second-line generic antiretroviral drugs are of great value in developing countries, there are concerns regarding their quality. We studied a generic Lopinavir/ritonavir (200/50 mg; Arga-L, India) marketed in the Republic of Congo but not prequalified by WHO. Despite adequate quantitative and qualitative drug content, Arga-L had a bio-availablility of 10% compared with Kaletra. To avoid selection of drug-resistant HIV, rigorous pharmacological monitoring of generic drugs not prequalified by WHO must be a priority.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Inhibitors of Viral Protein Synthesis
Subviral Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion

